We could not find any results for:
Make sure your spelling is correct or try broadening your search.
This article was automatically generated by MarketWatch using technology from Automated Insights. International stocks trading in New York closed lower Friday, as the S&P/BNY Mellon index of...
By Chris Wack Biophytis shares fell 11% to $2.40 after the company said it has filed for a pre-submission meeting request with the Food and Drug Administration to discuss filing for emergency use...
PARIS and CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biotechnology company...
PARIS and CAMBRIDGE, Mass., July 02, 2020 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company specialized in the development of drug...
All resolutions within the competence of the Ordinary General Meeting adoptedSecond notice to reconvene the Extraordinary General Meeting to be held in the coming weeks PARIS and CAMBRIDGE...
Provides funding for additional preclinical experiments and for the MYODA preparations for the clinical study in Duchenne muscular dystrophy (DMD) PARIS and CAMBRIDGE, Mass., June 13, 2019...
PARIS and CAMBRIDGE, Mass., June 07, 2019 (GLOBE NEWSWIRE) -- Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics for...
Files 2018 Annual Report with the AMFProvides first quarter 2019 financial statementsEnters into intellectual property agreement with Stanislas Veillet PARIS and CAMBRIDGE, Mass., May 22, 2019...
PARIS and CAMBRIDGE, Mass., May 22, 2019 (GLOBE NEWSWIRE) -- Biophytis (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics for...
Clinical execution and advancement of our SARA program, including initiation of the SARA-INT Phase 2b clinical trial for sarcopeniaLaunch of our MYODA program for Duchenne muscular dystrophy...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0157 | 5.31842818428 | 0.2952 | 0.3299 | 0.29 | 26021 | 0.29586344 | DE |
4 | -0.0006 | -0.192616372392 | 0.3115 | 0.39 | 0.28 | 58773 | 0.3130175 | DE |
12 | -0.1891 | -37.82 | 0.5 | 0.505 | 0.28 | 40936 | 0.34940454 | DE |
26 | -0.3891 | -55.5857142857 | 0.7 | 1.4 | 0.28 | 56225 | 0.53296282 | DE |
52 | 0.3051 | 5260.34482759 | 0.0058 | 1.4 | 0.0021 | 7827326 | 0.00592996 | DE |
156 | -0.1889 | -37.7951180472 | 0.4998 | 1.4 | 0.0021 | 5803336 | 0.0307196 | DE |
260 | 0.1245 | 66.7918454936 | 0.1864 | 2.73 | 0.0021 | 4903589 | 0.25611761 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions